Pyxis Oncology is a biotechnology business based in the US. Pyxis Oncology shares (PYXS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.10 – a decrease of 49.88% over the previous week. Pyxis Oncology employs 54 staff and has a trailing 12-month revenue of around $16.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.10 |
|---|---|
| 52-week range | $1.48 - $6.85 |
| 50-day moving average | $3.71 |
| 200-day moving average | $4.06 |
| Wall St. target price | $10.67 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.06 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.82 from 2024-11-20
| 1 week (2024-11-15) | -8.83% |
|---|---|
| 1 month (2024-10-23) | 5.82% |
| 3 months (2024-08-22) | 4.66% |
| 6 months (2024-05-22) | -2.05% |
| 1 year (2023-11-22) | 172.86% |
|---|---|
| 2 years (2022-11-22) | 185.07% |
| 3 years (2021-11-22) | 12.38 |
| 5 years (2019-11-19) | N/A |
| Revenue TTM | $16.1 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -21.06% |
| Return on equity TTM | -39.34% |
| Profit margin | 0% |
| Book value | $2.59 |
| Market Capitalization | $124.9 million |
TTM: trailing 12 months
We're not expecting Pyxis Oncology to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Pyxis Oncology's shares have ranged in value from as little as $1.48 up to $6.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pyxis Oncology's is 1.276. This would suggest that Pyxis Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Pyxis Oncology's beta into context you can compare it against those of similar companies.
Pyxis Oncology, Inc. , a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.